Your browser doesn't support javascript.
Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation.
Maniscalco, Mauro; Ambrosino, Pasquale; Fuschillo, Salvatore; Stufano, Silvia; Sanduzzi, Alessandro; Matera, Maria Gabriella; Cazzola, Mario.
  • Maniscalco M; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  • Ambrosino P; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  • Fuschillo S; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  • Stufano S; Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  • Sanduzzi A; Section of Respiratory Diseases, Department of Clinical Medicine and Surgery, Monaldi Hospital, University of Naples Federico II, Naples, Italy.
  • Matera MG; Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Cazzola M; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. Electronic address: mario.cazzola@uniroma2.it.
Respir Med ; 182: 106401, 2021 06.
Article in English | MEDLINE | ID: covidwho-1180018
ABSTRACT

BACKGROUND:

The usefulness of bronchodilators in coronavirus diseases 2019 (COVID-19) survivors is still uncertain, especially for patients with a concomitant obstructive lung disease. We aimed at verifying the level of bronchodilator reversibility in COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation after the acute phase.

METHODS:

We enrolled 105 consecutive patients referring to the Pulmonary Rehabilitation Unit of Istituti Clinici Scientifici Maugeri Spa SB, IRCCS of Telese Terme, Benevento, Italy after being discharged from the COVID-19 acute care ward and after recovering from acute COVID-19 pneumonia. All subjects performed a spirometry before and after inhalation of salbutamol 400 µg to determine the bronchodilation response within 48 h of admission to the unit.

RESULTS:

All patients had suffered from a moderate to severe COVID-19, classified 3 or 4 according to the WHO classification, Seventeen patients had concomitant obstructive lung disease (14 suffering from COPD and 3 from asthma). FEV1 after salbutamol improved on average by 41.7 mL in the entire examined sample, by 29.4 mL in subjects without concomitant obstructive lung diseases, by 59.3 mL in COPD patients and by 320.0 mL in asthma patients. Mean FVC after salbutamol improved by 65.7 mL in the entire examined sample, by 52.5 mL in subjects without concomitant obstructive lung diseases, by 120.0 mL in COPD patients, and by 200.0 mL in asthma patients.

CONCLUSIONS:

This study suggests that a treatment with bronchodilators must always be taken into consideration in post-COVID-19 patients because it can induce a functional improvement that, even if small, can facilitate the breathing of these patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bronchodilator Agents / Pulmonary Disease, Chronic Obstructive / COVID-19 / Lung Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Med Year: 2021 Document Type: Article Affiliation country: J.rmed.2021.106401

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Bronchodilator Agents / Pulmonary Disease, Chronic Obstructive / COVID-19 / Lung Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Med Year: 2021 Document Type: Article Affiliation country: J.rmed.2021.106401